



THE HPV
VACCINE
EXAMPLE

2012-13

THE PRESIDENT'S
CANCER PANEL

PRESIDENT'S CANCER PANEL UPDATE

NATIONAL VACCINE ADVISORY COMMITTEE

2/5/2013

Barbara K. Rimer, DrPH

PCP Mission

- **The Panel shall monitor the development and execution of the activities of the National Cancer Program, and shall report directly to the President.**
- **Any delays or blockages in rapid execution of the Program shall immediately be brought to the attention of the President.**

PCP Members

- **Barbara K. Rimer, DrPH,**
*Univ. of North Carolina
at Chapel Hill (Chair)*
- **Owen N. Witte, MD,**
*University of California
Los Angeles (Member)*
- **Hill Harper, JD,**
*Cancer Survivor,
Actor and Best-Selling
Author, Los Angeles, CA
(Member)*



Cancer Indications for Gardasil

-----INDICATIONS AND USAGE-----

GARDASIL is a vaccine indicated in girls and women 9 through 26 years of age for the prevention of the following diseases caused by Human Papillomavirus (HPV) types included in the vaccine:

- Cervical, vulvar, vaginal, and anal cancer caused by HPV types 16 and 18
- Genital warts (condyloma acuminata) caused by HPV types 6 and 11

Precancerous or Dysplastic Lesions

And the following precancerous or dysplastic lesions caused by HPV types 6, 11, 16, and 18:

- Cervical intraepithelial neoplasia (CIN) grade 2/3 and Cervical adenocarcinoma *in situ* (AIS)
- Cervical intraepithelial neoplasia (CIN) grade 1
- Vulvar intraepithelial neoplasia (VIN) grade 2 and grade 3
- Vaginal intraepithelial neoplasia (VaIN) grade 2 and grade 3
- Anal intraepithelial neoplasia (AIN) grades 1, 2, and 3

GARDASIL is indicated in boys and men 9 through 26 years of age for

Accelerating Progress in Cancer Prevention: The HPV Vaccine Example

Four Workshops (3/4 completed)

1. **HPV Vaccination as a Model for Cancer Prevention**
2. **Achieving Widespread HPV Vaccine Uptake**
3. **Creating an Integrated HPV Vaccination and Screening Program**
4. **Challenges of Global HPV Vaccination**

Draft Priority Actions to Increase HPV Vaccine Uptake

Monitoring & Surveillance

- **Strengthen vaccine registries (*w/reminder systems*) and enable linkage to cancer registries for monitoring and surveillance.**
- **Endorse Healthy People 2020 vaccination goals for females; and encourage male vaccination goal.**

Draft Priority Actions

Physicians/ Providers

- **Educate physicians/other health providers about cancer prevention benefits and efficacy of HPV vaccines.** (*Set practice goals and use/modify QI practices.*) **Provide tools.**
- **Consider HPV vaccination as part of broader adolescent health platform.**
- **Encourage policies that permit pharmacist-administered HPV vaccines.**
- **Encourage school-located vaccination programs.**

Draft Priority Actions

Communication

- **Conduct consumer-focused campaign** (*for adolescents/parents/caregivers/others*) **that focuses on vaccination for males and females, using a range of strategies, including social media.**
- **Special attention to geographic areas with low vaccination rates**

Draft Priority Actions

Research

Encourage research to...

- **Monitor ongoing studies to assess whether <3 vaccine doses are sufficient for efficacy/duration of protection.**
- **Monitor clinical and virologic impact of vaccination at population level.**
- **Explain natural history of oropharyngeal HPV infections.**

Possible Priority Actions

Global



Contact Information

President's Cancer Panel

9000 Rockville Pike

Bld. 31 /B2B37

Bethesda, MD 20892

pcp-r@mail.nih.gov

<http://pcp.cancer.gov>